La cadena de opciones muestra datos clave de las opciones de acciones de CureVac a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CureVac..

CureVac (NASDAQ:CVAC) Bolsa, Cadena de Opciones

CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

Un trabajador lechero en Nevada da positivo en gripe aviar H5N1. CDC investiga mientras la cepa se propaga en aves y ganado.

Gripe aviar en EE.UU.: trabajador lechero en Nevada da positivo

CureVac NV

Earnings

Press Releases

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders

Small Cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders

CureVac Announces Voting Results of General Meeting

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

BNTX

CTLP

HLGN

MTWO

SOAR

VERV

Ardelyx

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

GRAIL

Janux Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Precigen

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Upstream Bio

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Jefferies

JMP Securities

Leerink Partners

B of A Securities

Comments

CureVac

CureVac (CVAC) Opciones

CureVac (NASDAQ:CVAC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL